Presentation and mortality of primary biliary cirrhosis in older patients

Size: px
Start display at page:

Download "Presentation and mortality of primary biliary cirrhosis in older patients"

Transcription

1 Age and Ageing 2000; 29: Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET F. BASSENDINE 2,OLIVER F. W. JAMES 1,2 2000, British Geriatrics Society 1 Department of Medicine (Geriatrics), University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK 2 Centre for Liver Research, University of Newcastle upon Tyne, Newcastle upon Tyne, UK Address correspondence to: O. F. W. James. Fax: (þ44) o.f.w.james@ncl.ac.uk Abstract Objectives: many patients with primary biliary cirrhosis present for the first time aged over 65, but it is unclear whether the disease is different in older patients. We have examined presentation and mortality in relation to age at which primary biliary cirrhosis was first suspected clinically. Design: we identified 1023 patients from our regional primary biliary cirrhosis database with definite or probable primary biliary cirrhosis (689 definite); 397 (39%) presented aged 65. Definite primary biliary cirrhosis was defined as a positive antimitochondrial antibody titre 1/40, abnormal liver enzymes and compatible/diagnostic histology; probable as the presence of two of these indications. Results: there was no difference in presenting clinical features between the older and younger groups. Older patients were significantly less likely than younger to have had liver biopsy (50% vs 78%; P < 0:001). The 1023 patients had been followed for 8561 patient years. Follow-up was shorter (5.9 4 vs years; P < 0:001) in the older group because of higher cumulative mortality (59% vs 33%; P < 0:001). Liver-related deaths were significantly commoner in the older group (18% vs 13%; P < 0:05). The mortality ratio for liver deaths (liver deaths per year of follow-up) was 2.4 times higher in the older group (0.031 vs 0.013). Conclusions: patients with primary biliary cirrhosis who are over and under 65 have similar features on presentation. The annual risk of liver death is 2.4 times higher in those presenting over 65, reaffirming the importance of age as an independent prognostic factor in an unselected primary biliary cirrhosis population. Keywords: autoimmune disease, elderly, liver, primary biliary cirrhosis Introduction Primary biliary cirrhosis (PBC) is an autoimmune liver disease typically presenting in middle-aged women with progressive cholestatic jaundice [1]. It was thought to be a rare disease, often leading to death from liver failure. However, in recent years perception of the condition has changed. PBC is now often diagnosed at an asymptomatic stage, through the detection of either abnormal serum liver biochemistry or autoantibodies. The changing clinical spectrum of PBC results partly from earlier diagnosis and partly from the recognition of antimitochondrial antibody (AMA) as a marker for the disease [2, 3]. Several large series from tertiary referral centres have shown that the mean age of diagnosis is now between 55 and 60 years [4], implying that many patients are over 65 on first presentation. When prognostic markers for PBC have been examined using multivariate analysis, old age is always an adverse risk factor [5]. Furthermore, the dynamic model from the Mayo Clinic has confirmed that increasing age continues to have an independent and adverse effect on prognosis, implying that the disease course in elderly subjects may be more rapid [6]. Conversely, other studies have speculated as to whether PBC is a more benign disease in elderly patients or the same disease presenting later in life [7, 8]. We have examined the features of PBC in patients presenting for the first time at the age of 65 years or over and compared them to features seen in younger subjects. We have also examined mortality, to determine whether or not advanced age carries an adverse prognosis in PBC. Methods Patients in whom a diagnosis of PBC has been considered in North-East England have been entered 305

2 J. L. Newton et al. into a PBC database. This was established to carry out an epidemiological study of PBC in a stable population, resident in a defined geographical area in northern England (defined by post code) between January 1987 and December The case-finding methodology for this study has been described previously [9]. Briefly, we (i) included all PBC patients attending the liver clinic at Freeman Hospital, Newcastle, (ii) sought patients from all gastroenterologists in the region, (iii) used the Regional Hospital Information System to identify all patients with biliary cirrhosis (ICD-9 codes 571 6) from the 13 hospitals in the region, (iv) examined autoimmune antibody profiles carried out in the region between 1987 and 1994 and identified those with positive AMA titre 1:40 ( profiles examined 85% of all profiles carried out), and (v) obtained death certificates for patients who died of biliary cirrhosis in the region (ICD-9 codes 571 6) from the Office of National Statistics. In the present study, we also included patients who had been excluded from the epidemiological study because they lived outside the strictly defined study area (but still within the North-East) or because they had died before 1 January 1987 or been diagnosed after 31 December Thus, this case series includes both patients in the epidemiological study [9] and all other patients from North-East England in whom a diagnosis of PBC was considered between 1968 and December We examined retrospectively the hospital case records of all patients in whom a diagnosis of PBC was considered. In the patients with no known case records we approached the family general practitioner for information on the patient (n ¼ 20). We invited these patients (by post), to attend the PBC clinic where we took their history, examined them and carried out blood tests. The date a presumed diagnosis of PBC (i.e. date of presentation ) was made was the time at which two of the following three diagnostic criteria were first fulfilled and recorded in case records: (i) positive AMA titre (1:40), (ii) abnormal liver function tests (LFT i.e. bilirubin, serum transaminases, alkaline phosphatase) and (iii) compatible/diagnostic liver histology for PBC. Despite the presence of at least two of the diagnostic criteria entered in the case records, the diagnosis of PBC may not have been considered by the physician responsible for the patient at that time. From the regional database, we identified individuals with definite or probable PBC. A definite diagnosis was defined as the presence of all three diagnostic criteria. Probable PBC was defined as two of the three criteria [10]. We describe those aged 65 at the time of presumed diagnosis as the older group, and those aged <65 as the younger group. We recorded clinical, biochemical and liver histology data for all subjects on the regional PBC database. As biochemical and serological results are from different laboratories and reference ranges may vary, we expressed data as a ratio of the normal range. All liver biopsies were reviewed by one of two histopathologists and classified according to current histological criteria into early (Scheuer stage I/II) and advanced (Scheuer stage III/IV) [11]. Results are expressed as mean (SD) or median. We performed comparisons with the Student s unpaired Table 1. Patients with primary biliary cirrhosis presenting for the first time before or after the age of No. of subjects Men (% total) 42 (11) 60 (10) Primary biliary cirrhosis (% of total) a Definite 200 (50) 489 (78) Probable 197 (50) 137 (22) a Definite primary biliary cirrhosis: compatible histology, antimitochondrial antibody-positive and abnormal liver function tests; probable: two of the above. Figure 1. Proportions of subjects presenting for the first time before (A) (B) and after the age of 65 with symptoms at presentation that were: asymptomatic of liver disease (antimitochondrial antibody-positive, abnormal liver function tests), symptomatic of primary biliary cirrhosis (Sjogren s syndrome, pruritus, weight loss, xanthelasma, fatigue, right upper quadrant discomfort) or complicated symptoms of portal hypertension or liver failure (jaundice, ascites, varices, encephalopathy, hepatorenal syndrome). 306

3 Primary biliary cirrhosis in older people Table 2. Levels of biochemical markers in subjects presenting with definite or probable primary biliary cirrhosis for the first time before or after the age of 65 Mean ratio of abnormal result (SD) a, by age at presentation Definite Probable Definite Probable... Bilirubin 1.7 (1.9) b 1.24 (1) 1.67 (2) b 1.22 (1.5) Albumin 0.97 (0.07) 0.97 (0.08) 0.98 (0.06) 0.98 (0.07) Alkaline phosphatase 4.85 (6.6) b 2.4 (2.3) 4 (3.4) b 2 (1.9) Transaminase 2.25 (2.9) b 1.6 (3) 2.4 (2.6) b 1.4 (1) a Expressed as a ratio to normal: abnormal bilirubin, alkaline phosphatase, transaminases >1, albumin <1. b Ratios are significantly higher in those with a definite diagnosis compared with those with a probable diagnosis (P < 0:05). t-test for parametric variables and the x 2 test and Mann Whitney U test where appropriate. A statistically significant result is when P < 0:05. We obtained ethical permission for the collection of data and development of the database from the joint Newcastle hospitals/university ethical committee and all other ethical committees in the study region. All subjects gave informed consent for inclusion. Results Presentation From the regional database we identified 1023 individuals with definite or probable PBC presenting between 1968 and Three hundred and ninetyseven presented at or after the age of 65; 626 presented before the age of 65 (Table 1). Six hundred and eighty-nine (67%) had definite PBC. Of the 334 with probable PBC, 297 (89%) were AMA-positive with abnormal LFT but had not had the diagnosis confirmed by liver biopsy, 23 (7%) were AMAnegative but with compatible biopsy and abnormal LFT ( autoimmune cholangiopathy regarded as clinically indistinguishable from PBC [12]) and 14 (4%) were AMA-positive and had compatible liver histology but normal LFT (these patients have an 80% chance of progressing to classical disease [13]). There was no significant difference in the proportions of those presenting with no symptoms or complications of liver disease at the time of presumed diagnosis in the older compared to the younger group (Figure 1). However, significantly more of the younger group had non-specific minor symptoms of PBC (24.5% versus 16.5%). Investigations There were no significant differences in the markers of disease severity at presentation (serum albumin and bilirubin) between those who had presented before or after the age of 65 in either the definite PBC group or the probable PBC group. Neither were there any significant difference in serum alkaline phosphatase concentrations or transaminase between the age groups at presumed diagnosis (Table 2). The older patients were significantly less likely to have had the diagnosis confirmed histologically than the younger group (P < 0:001). Of the 689 who had had liver biopsy, staging details were available in 491 (71%). In those in whom a biopsy was performed (132/ 200: 66% of biopsies in those over 65 at the time of presentation, 359/489: 73% of biopsies in the younger group), the frequency of advanced histological disease (i.e. stage III/IV) was significantly higher in those patients presenting over 65 than in younger patients (P < 0:01). In those who had liver biopsy, when grouped according to age at first presentation, the ratio of the number of those with cirrhotic to precirrhotic disease increased with advancing age (Figure 2). Notwithstanding the lower proportion of patients receiving biopsies in the older group, patients over 65 Figure 2. The ratio of the numbers of individuals with advanced/early primary biliary cirrhosis (cirrhotic/ precirrhotic) by age at first presentation. 307

4 J. L. Newton et al. Table 3. Histological stage in those who had liver biopsy after presenting with primary biliary cirrhosis for the first time before (n ¼ 489) or after (n ¼ 200) the age of No. (and %) of subjects Early (stage I/II) 48 (36) 182 (51) Advanced (stage III/IV) 84 (64) a 177 (49) Median time from presumptive to histological diagnosis, months (range) 3 (0 138) 4 (0 195) a Significantly more than in the younger group. at presentation did not wait longer for histological confirmation (Table 3). Mortality We followed the 1023 patients for 8461 patient years. The older group were followed-up for a significantly shorter time mean (SD) 5.9 (4.0) years versus 9.8 (5.5) years for the younger group (P < 0:001) because of the higher cumulative mortality in the patients presenting for the first time at 65 or older (P < 0:001). When considering cause of death (death certificate and case note review), death from liver-related causes was significantly more frequent in the older group (P < 0:05). We calculated mortality ratios using the formula shown in Table 4. In the total groups, the mortality ratio in the younger group was less than half that found for the older group (0.013 versus 0.03). None of the older group had liver transplantation whilst 48 of the younger group received transplants. We recalculated liver-related mortality ratios after excluding the group that received transplants and found that the mortality ratio was no different (0.013 in those <65 who did not undergo transplants versus in those who did). Discussion Presentation The two previous studies of PBC in older people have involved small numbers of patients and incomplete follow-up data. The study of Hislop et al. [7] included only seven patients presenting over 70, with mean follow-up of 25 months. Lehmann et al. [8] examined 35 patients who were over 65 at presentation, with mean follow-up around 55 months. In our case series, we examined the presentation of PBC in 1023 patients, 39% of whom were aged 65 or over at the time of presumed diagnosis. We confirm that PBC does not appear to be a different disease in elderly people as symptoms at first presentation are neither more nor less severe in younger than older individuals. Investigations Biochemical measures of severity did not differ between older and younger groups. Fewer of those aged 65 had a definitive diagnosis of PBC (i.e. had had liver biopsy). It may be argued that making a definite diagnosis of PBC in an elderly patient is of little benefit, particularly as there is no treatment of proven benefit for PBC (although ursodeoxycholic acid delays the development of oesophageal varices even in those with stage IV disease [14]). Liver biopsy is a relatively safe procedure in older patients, with no greater mortality than in younger individuals [15]. In our study, we were surprised to find no delay from the time of clinical suspicion to definitive diagnosis in older people who did have a liver biopsy. Perhaps biopsy was performed in older patients with Table 4. Deaths and liver-related mortality ratios a in those presenting with primary biliary cirrhosis primary before or after the age of 65, and in those who had had liver transplantation (none of whom were in the older group) Women Men Total Women Men Transplanted Total... No. in group No. (and %) of deaths All causes 209 (59) 25 (60) 234 (59) 185 (33) 22 (37) 10 (21) 207 (33) Liver-related (A) 67 (19) 4 (10) 71 (18) 74 (13) 7 (12) 4 (8) 81 (13) Years of follow-up (B) Liver-related mortality ratio (A/B) a Number of liver-related deaths/total number of years at risk (i.e. sum of years of follow-up). 308

5 Primary biliary cirrhosis in older people more severe disease, but there was no significant difference in the markers of severity (serum albumin and bilirubin) between older and younger subjects who had liver biopsy. In most instances in which patients (particularly older patients) did not have liver biopsy, it was thought by the responsible clinician that biopsy would not add to the management of their patient. The frequency of advanced-stage disease (Scheuer stage III/IV) where biopsy was performed was significantly higher in those presenting for the first time over the age of 65. This increased proportion of those with advanced disease with advancing age could suggest either that these individuals are presenting later in the same disease or that there is a reduced willingness to consider liver biopsy in those over 65. Mortality It is not surprising that overall mortality was higher in the older group (59% versus 33%) since there are more deaths in the older group from non-liver-related causes. However, we have confirmed other studies that examined independent prognostic variables in smaller groups: in over 1000 PBC patients whom we followed for 8561 years, the liver-related mortality ratio was over twice as great in women presenting over age 65 (3%/ year) than in those presenting below that age (1.3%/ year). There is little clinical evidence to support the idea that this was because older patients had presented with more advanced disease. As with many other diseases, the ability of the ageing organism to withstand the severe stress of advanced liver disease and possible age-related impaired homeostasis may be responsible [16]. Key points Almost 40% of subjects with primary biliary cirrhosis present for the first time at or after the age of 65. Primary biliary cirrhosis should be included in the differential diagnosis in older people with abnormal liver blood tests. The mortality ratio is higher in individuals who present for the first time when they are over 65. References 1. Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973; 289: Mitchison HC, Bassendine MF, Hendrick A et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 1986; 6: Metcalf JV, Mitchison HC, Palmer JM et al. Natural history of early primary biliary cirrhosis. Lancet 1996; 348: James O, Watson AJ, Macklon AF. Primary biliary cirrhosis a revised clinical spectrum. Lancet 1981: Weisner RH, Porayko MK, Dickson ER et al. Selection and timing of transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992; 16: Murtaugh PA, Dickson ER, Van Dam GM et al. Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. Hepatology 1994; 20: Hislop WS, Hopwood D, Bouchier IAD. Primary biliary cirrhosis in elderly females. Age Ageing 1982; 11: Lehmann AB, Bassendine MF, James OFW. Is primary biliary cirrhosis a different disease in the elderly? Gerontology 1995; 31: Metcalf JV, Bhopal RS, Gray J et al. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne. Int J Epidemiol 1997; 26: Metcalf JV, Howel D, Bhopal RS et al. Primary biliary cirrhosis epidemiology helping the clinician. Br Med J 1996; 312: Scheuer PJ. Liver Biopsy Interpretation. Baltimore: Williams and Wilkins, Heathcote J. Autoimmune cholangitis. Gut 1997; 40: Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OFW. Natural history of primary biliary cirrhosis. Lancet 1996; 348: Lindor KD, Jorgensen RA, Therneau TM et al. Ursodeoxycholic acid delays the onset of oesophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 12: Gilmore IT, Burroughs A, Murray-Lyon IM et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: Shock NW. Ageing and physiological systems. J Chron Dis 1983; 36: Received 21 June 1999; accepted in revised form 16 December

Primary Biliary Cirrhosis Once Rare, Now Common in the United Kingdom?

Primary Biliary Cirrhosis Once Rare, Now Common in the United Kingdom? Primary Biliary Cirrhosis Once Rare, Now Common in the United Kingdom? OLIVER F. W. J AMES, 1 RAJ BHOPAL, 2 DENISE HOWEL, 2 JACKIE GRAY, 2 ALASTAIR D. BURT, 1 AND JANE V. METCALF 1 There is a widespread

More information

R ecent estimates suggest that there are

R ecent estimates suggest that there are 865 LIVER Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort M I Prince, A Chetwynd, W L Craig, J V Metcalf, O F W James...

More information

Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks

Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope Background: April 21, 2016 Primary biliary cholangitis

More information

The True Impact of Fatigue in Primary Biliary Cirrhosis: A Population Study

The True Impact of Fatigue in Primary Biliary Cirrhosis: A Population Study GASTROENTEROLOGY 2002;122:1235 1241 The True Impact of Fatigue in Primary Biliary Cirrhosis: A Population Study JENNIFER GOLDBLATT,* PHILIP J. S. TAYLOR, TOBY LIPMAN, MARTIN I. PRINCE,* ANNA BARAGIOTTA,*

More information

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very

More information

Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN

Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN 2012 Annual Conference PSC Partners Seeking a Cure May 5, 2012 Primary Sclerosing Cholangitis Multifocal

More information

GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE

GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE Kalliopi Azariadis 1, Nikolaos K. Gatselis 1, Kalliopi Zachou 1, Vasiliki Lygoura 1, Pinelopi Arvaniti 1, Eirini I. Rigopoulou 1, Georgia

More information

Primary Biliary Cholangitis

Primary Biliary Cholangitis Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction

More information

New insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine

New insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine New insights in pathogenesis and therapy of primary biliary cholangitis Keith D. Lindor Dean Professor of Medicine OUTLINE PBC Epidemiology Diagnosis Treatment Incidence of PBC and PSC Trends Boonstra

More information

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT A

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT A CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:228 233 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT A Predictive Model for Fatigue and Its Etiologic Associations in Primary Biliary Cirrhosis JULIA

More information

Key Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto

Key Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis

More information

TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)

TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) URSO not indicated Therapy for PBC Difficulties Etiology is uncertain Therapies are based on ideas regarding pathogenesis Present medical therapies have a limited

More information

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? 22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization

More information

CLINICAL LIVER, PANCREAS, AND BILIARY TRACT. Epidemiology of Primary Biliary Cirrhosis in Victoria, Australia: High Prevalence in Migrant Populations

CLINICAL LIVER, PANCREAS, AND BILIARY TRACT. Epidemiology of Primary Biliary Cirrhosis in Victoria, Australia: High Prevalence in Migrant Populations GASTROENTEROLOGY 2004;127:470 475 CLINICAL LIVER, PANCREAS, AND BILIARY TRACT Epidemiology of Primary Biliary Cirrhosis in Victoria, Australia: High Prevalence in Migrant Populations SIDDHARTH SOOD, PAUL

More information

Diagnosis and Management of PBC

Diagnosis and Management of PBC Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in

More information

Hangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam

Hangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary

More information

Prolonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis

Prolonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis American Journal of Gastroenterology ISSN 0002-9270 C 2004 by Am. Coll. of Gastroenterology doi: 10.1111/j1572-0241.2004.04047.x Published by Blackwell Publishing Prolonged Follow-Up of Patients in the

More information

LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES

LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions

More information

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis

Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary

More information

Managing Abnormal Liver Blood Tests in Older People

Managing Abnormal Liver Blood Tests in Older People Peer-reviewed Hepatobiliary Diseases Managing Abnormal Liver Blood Tests in Older People James Frith, MB ChB, MRCP, Clinical Research Associate, Biomedical Research Centre in Ageing Liver Theme and Institute

More information

Hépatopathies auto-immunes

Hépatopathies auto-immunes 16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois

More information

Resident, PGY1 David Geffen School of Medicine at UCLA. Los Angeles Society of Pathology Resident and Fellow Symposium 2013

Resident, PGY1 David Geffen School of Medicine at UCLA. Los Angeles Society of Pathology Resident and Fellow Symposium 2013 Resident, PGY1 David Geffen School of Medicine at UCLA Los Angeles Society of Pathology Resident and Fellow Symposium 2013 85 year old female with past medical history including paroxysmal atrial fibrillation,

More information

age, serum levels of bilirubin, albumin, and aspartate aminotransferase

age, serum levels of bilirubin, albumin, and aspartate aminotransferase The Relative Role of the Child-Pugh Classification and the Mayo Natural History Model in the Assessment of Survival in Patients With Primary Sclerosing Cholangitis W. RAY KIM, JOHN J. POTERUCHA, RUSSELL

More information

What Is the Real Gain After Liver Transplantation?

What Is the Real Gain After Liver Transplantation? LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;

More information

ACG Clinical Guideline: Primary Sclerosing Cholangitis

ACG Clinical Guideline: Primary Sclerosing Cholangitis ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,

More information

Morning Report Presentation. Sarah Hughes, MD January 11, 2005

Morning Report Presentation. Sarah Hughes, MD January 11, 2005 Morning Report Presentation Sarah Hughes, MD January 11, 2005 Primary Biliary Cirrhosis! PBC is a chronic, progressive, cholestatic liver disease of unknown cause that usually affects middle-aged women

More information

Current Concepts in the Management and Treatment of PBC & PSC

Current Concepts in the Management and Treatment of PBC & PSC Current Concepts in the Management and Treatment of PBC & PSC Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London A family affair? Central vein Hepatocytes

More information

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS

More information

Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid

Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid Alimentary Pharmacology and Therapeutics Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid K. M. Boberg*,, T. Wisløff, K. S. Kjøllesdal, H. Støvring & I.

More information

Clinical Significance of Serum Bilirubin Levels Under Ursodeoxycholic Acid Therapy in Patients With Primary Biliary Cirrhosis

Clinical Significance of Serum Bilirubin Levels Under Ursodeoxycholic Acid Therapy in Patients With Primary Biliary Cirrhosis Clinical Significance of Serum Bilirubin Levels Under Ursodeoxycholic Acid Therapy in Patients With Primary Biliary Cirrhosis ANNE-MARIE BONNAND, 1 E. JENNY HEATHCOTE, 2 KEITH D. LINDOR, 3 AND RENÉE EUGÉNIE

More information

Ocaliva (obeticholic acid tablets)

Ocaliva (obeticholic acid tablets) Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage

More information

PBC treatment: the present and future. Maggie Bassendine Professor of Hepatology

PBC treatment: the present and future. Maggie Bassendine Professor of Hepatology PBC treatment: the present and future Maggie Bassendine Professor of Hepatology Primary biliary cirrhosis 20-25yrs OLT/ Death Symptoms: Fatigue, itching, jaundice Autoimmune disease: Focal small bile duct

More information

An integrated care pathway improves quality of life in Primary Biliary Cirrhosis

An integrated care pathway improves quality of life in Primary Biliary Cirrhosis Q J Med 2008; 101:535 543 doi:10.1093/qjmed/hcn043 Advance Access published on 3 April 2008 An integrated care pathway improves quality of life in Primary Biliary Cirrhosis DAVID E.J. JONES, KATY SUTCLIFFE,

More information

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:

More information

Primary Biliary Cirrhosis at Hospital Kuala Lumpur: A Study of 11 Cases Seen Between

Primary Biliary Cirrhosis at Hospital Kuala Lumpur: A Study of 11 Cases Seen Between Primary Biliary Cirrhosis at Hospital Kuala Lumpur: A Study of 11 Cases Seen Between 1992 and 1999 R Kananathan, MRCPI, R L Suresh, MRCP, I Merican, FRCP, Department of Medicine, Hospital Kuala Lumpur,

More information

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma

More information

Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs

Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs PROFESSIONAL ISSUES Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs Simon Whalley, Prasanthi Puvanachandra, Atman Desai and Hugh Kennedy

More information

CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease

CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months

More information

Primary biliary cirrhosis (PBC) is a progressive cholestatic

Primary biliary cirrhosis (PBC) is a progressive cholestatic AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Comparative Analysis from Two Centers Anna Cavazza, 1 Llorenç

More information

Autoimmune hepatitis

Autoimmune hepatitis Autoimmune hepatitis: Autoimmune hepatitis a spectrum within a spectrum Alastair Burt Professor of Pathology and Dean of Clinical Medicine Newcastle University Spectrum of autoimmune liver disease Autoimmune

More information

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate

More information

Incidence of Primary Biliary Cholangitis in a Rural Midwestern Population

Incidence of Primary Biliary Cholangitis in a Rural Midwestern Population Clinical Medicine & Research Volume 15, Number 1-2: 13-18 2017 Marshfield Clinic Health System clinmedres.org Original Research Incidence of Primary Biliary Cholangitis in a Rural Midwestern Population

More information

URSODIOL FOR PRIMARY SCLEROSING CHOLANGITIS URSODIOL FOR PRIMARY SCLEROSING CHOLANGITIS. Patients

URSODIOL FOR PRIMARY SCLEROSING CHOLANGITIS URSODIOL FOR PRIMARY SCLEROSING CHOLANGITIS. Patients KEITH D. LINDOR, M.D., FOR THE MAYO PRIMARY SCLEROSING CHOLANGITIS URSODEOXYCHOLIC ACID STUDY GROUP* ABSTRACT Background There is no satisfactory medical therapy for patients with primary sclerosing cholangitis.

More information

Gastroenterology. Certification Examination Blueprint. Purpose of the exam

Gastroenterology. Certification Examination Blueprint. Purpose of the exam Gastroenterology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified gastroenterologist

More information

Overview of PSC Making the Diagnosis

Overview of PSC Making the Diagnosis Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases

More information

POST TRANSPLANT OUTCOMES IN PSC

POST TRANSPLANT OUTCOMES IN PSC POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners

More information

A Case of Antimitochondrial Antibody Negative Primary Biliary Cirrhosis from Bangladesh and Review of Literature

A Case of Antimitochondrial Antibody Negative Primary Biliary Cirrhosis from Bangladesh and Review of Literature EJOHG Roksana Begum et al CASE REPORT 10.5005/jp-journals-10018-1150 A Case of Antimitochondrial Antibody Negative Primary Biliary Cirrhosis from Bangladesh and Review of Literature 1 Roksana Begum, 1

More information

Putting NICE guidance into practice. Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443)

Putting NICE guidance into practice. Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443) Putting NICE guidance into practice Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443) Published: April 2017 Summary Obeticholic acid is recommended as an option

More information

Autoimmune Liver Diseases

Autoimmune Liver Diseases 2nd Pannonia Congress of pathology Hepato-biliary pathology Autoimmune Liver Diseases Vera Ferlan Marolt Institute of pathology, Medical faculty, University of Ljubljana Slovenia Siofok, Hungary, May 2012

More information

White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers

White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers Hardy et al. BMC Gastroenterology 2013, 13:55 RESEARCH ARTICLE Open Access White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers Timothy Hardy

More information

The Natural History of Small-Duct Primary Sclerosing Cholangitis

The Natural History of Small-Duct Primary Sclerosing Cholangitis GASTROENTEROLOGY 2008;134:975 980 The Natural History of Small-Duct Primary Sclerosing Cholangitis EINAR BJÖRNSSON,* ROLF OLSSON,* ANNIKA BERGQUIST, STEFAN LINDGREN, BARBARA BRADEN, ROGER W. CHAPMAN, KIRSTEN

More information

Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785

Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785 Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785 Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment

More information

Pediatric PSC A children s tale

Pediatric PSC A children s tale Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;

More information

GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint

GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Gastroenterology MOC exam blueprint Based on feedback from physicians that MOC assessments

More information

Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful?

Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful? CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:935 940 Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful? REGAN L. EBBESON* and RICHARD

More information

Primary sclerosing cholangitis (PSC) is a chronic

Primary sclerosing cholangitis (PSC) is a chronic Predicting Clinical and Economic Outcomes After Liver Transplantation Using the Mayo Primary Sclerosing Cholangitis Model and Child-Pugh Score Jayant A. Talwalkar, * Eric Seaberg, W. Ray Kim, * and Russell

More information

Jaundice. Agnieszka Dobrowolska- Zachwieja, MD, PhD

Jaundice. Agnieszka Dobrowolska- Zachwieja, MD, PhD Jaundice Agnieszka Dobrowolska- Zachwieja, MD, PhD Jaundice definition Jaundice, as in the French jaune, refers to the yellow discoloration of the skin. It arises from the abnormal accumulation of bilirubin

More information

A Prospective Trial of Colchicine and Methotrexate in the Treatment of Primary Biliary Cirrhosis

A Prospective Trial of Colchicine and Methotrexate in the Treatment of Primary Biliary Cirrhosis GASTROENTEROLOGY 1999;117:1173 1180 A Prospective Trial of Colchicine and Methotrexate in the Treatment of Primary Biliary Cirrhosis MARSHALL M. KAPLAN, CHRISTOPHER SCHMID, DAWN PROVENZALE, ARCHNA SHARMA,

More information

OCALIVA (obeticholic acid) oral tablet

OCALIVA (obeticholic acid) oral tablet OCALIVA (obeticholic acid) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Healthy Liver Cirrhosis

Healthy Liver Cirrhosis Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The

More information

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic

More information

Chronic Cholestatic Liver Diseases

Chronic Cholestatic Liver Diseases Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research

More information

Primary biliary cirrhosis (PBC) is an autoimmune

Primary biliary cirrhosis (PBC) is an autoimmune Early Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis of Primary Biliary Cirrhosis: Results of a 14-Year Cohort Study Li-Na Zhang, 1,2 * Tian-Yan Shi, 1,2 * Xu-Hua Shi, 1,2 Li Wang,

More information

Primary biliary cirrhosis (PBC) and primary sclerosing

Primary biliary cirrhosis (PBC) and primary sclerosing Mortality Attributable to Cholestatic Liver Disease in the United States Flavia D. Mendes, 1 W. Ray Kim, 2 Rachel edersen, 3 Terry Therneau, 3 and Keith D. Lindor 2 In the past 2 decades, important advances

More information

UNIVERSITY OF CALGARY. Epidemiology and outcomes of primary biliary cirrhosis in the Calgary. Health Region: A population-based study

UNIVERSITY OF CALGARY. Epidemiology and outcomes of primary biliary cirrhosis in the Calgary. Health Region: A population-based study UNIVERSITY OF CALGARY Epidemiology and outcomes of primary biliary cirrhosis in the Calgary Health Region: A population-based study by Robert Paul Myers A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES

More information

A Case of Well-differentiated Hepatocellular Carcinoma Arising in Primary Biliary Cirrhosis

A Case of Well-differentiated Hepatocellular Carcinoma Arising in Primary Biliary Cirrhosis Kobe J. Med. Sci., Vol. 49, No. 2, pp. 39-43, 2003 A Case of Well-differentiated Hepatocellular Carcinoma Arising in Primary Biliary Cirrhosis YOSHIHIKO YANO 1, SEITETSU YOON 1, YASUSHI SEO 1, TOSHIAKI

More information

Primary Biliary Cirrhosis

Primary Biliary Cirrhosis Primary Biliary Cirrhosis What is Primary Biliary Cirrhosis? Primary biliary cirrhosis (PBC) is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver called the

More information

Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score

Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 2012;18:375-382 Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune

More information

THE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES

THE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES THE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES AUTHORS: HIRSCHFIELD GM, DYSON JK, ALEXANDER GJ, CHAPMAN M, COLLIER J, HUBSCHER S, PATANWALA

More information

Risk stratification in PBC

Risk stratification in PBC Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive

More information

The Sheila Sherlock Royal Free Hepatology Postgraduate Course Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom

The Sheila Sherlock Royal Free Hepatology Postgraduate Course Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom The Sheila Sherlock Royal Free Hepatology Postgraduate Course 2019 Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom *Includes histopathology within talk # Includes radiology

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of

More information

Autoimmune Hepatitis in Clinical Practice

Autoimmune Hepatitis in Clinical Practice 1 Autoimmune Hepatitis in Clinical Practice Atif Zaman, MD MPH Professor of Medicine Senior Associate Dean for Clinical and Faculty Affairs School of Medicine Oregon Health & Science University Disclosure

More information

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,

More information

Quantitative fibrosis parameters highly predict esophageal-gastro varices in primary biliary cirrhosis

Quantitative fibrosis parameters highly predict esophageal-gastro varices in primary biliary cirrhosis European Review for Medical and Pharmacological Sciences Quantitative fibrosis parameters highly predict esophageal-gastro varices in primary biliary cirrhosis 2016; 20: 1037-1043 Q.-M. WU 1,2, X.-Y. ZHAO

More information

Chronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths

Chronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Terminology is confusing with pathologists and hepatologists using the same language BUT with different meanings. Chronic

More information

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently

More information

Sarah Landes October 23, 2014

Sarah Landes October 23, 2014 Sarah Landes October 23, 2014 A T-cell mediated inflammatory destruction of intralobular bile ducts progressively leading to cholestasis and cirrhosis 9:1 F to M ratio Mostly diagnosed between 30-60 years

More information

Primary Sclerosing Cholangitis Medical Management

Primary Sclerosing Cholangitis Medical Management Primary Sclerosing Cholangitis Medical Management Kapil Chopra M.D. Assistant Professor of Medicine Division of Transplant Medicine Mayo Clinic Arizona PSC Primary sclerosing cholangitis is a progressive

More information

Tratamiento endoscópico de la CEP. En quien como y cuando?

Tratamiento endoscópico de la CEP. En quien como y cuando? Tratamiento endoscópico de la CEP. En quien como y cuando? Andrés Cárdenas, MD, MMSc, PhD, AGAF, FAASLD GI / Liver Unit, Hospital Clinic Institut de Malalties Digestives i Metaboliques University of Barcelona

More information

Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease

Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1355 1360 Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease PIOTR MILKIEWICZ,*, HAYMAN BUWANESWARAN,* CATALINA

More information

Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015

Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015 Citation: (2017) 8, e116; doi:10.1038/ctg.2017.43 Official journal of the American College of Gastroenterology www.nature.com/ctg Epidemiology and Natural History of Primary Biliary Cholangitis in the

More information

Increased prevalence of primary sclerosing cholangitis among first-degree relatives

Increased prevalence of primary sclerosing cholangitis among first-degree relatives Journal of Hepatology 42 (2005) 252 256 www.elsevier.com/locate/jhep Increased prevalence of primary sclerosing cholangitis among first-degree Annika Bergquist*, Greger Lindberg, Susanne Saarinen, Ulrika

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function

More information

Primary biliary cirrhosis (PBC) is a rare chronic inflammatory CLINICAL LIVER, PANCREAS, AND BILIARY TRACT

Primary biliary cirrhosis (PBC) is a rare chronic inflammatory CLINICAL LIVER, PANCREAS, AND BILIARY TRACT GASTROENTEROLOGY 2005;128:297 303 CLINICAL LIVER, PANCREAS, AND BILIARY TRACT The Effect of Ursodeoxycholic Acid Therapy on the Natural Course of Primary Biliary Cirrhosis CHRISTOPHE CORPECHOT,* FABRICE

More information

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon

More information

Biomarkers of PSC. Steve Helmke, Ph.D.

Biomarkers of PSC. Steve Helmke, Ph.D. Biomarkers of PSC Steve Helmke, Ph.D. steve.helmke@ucdenver.edu Biomarkers of PSC Currently Used in Clinical Practice Biomarkers Used in Prognostic Models of PSC Wiesner et al, 1989 Age Bilirubin Biopsy

More information

Idiopathic adulthood ductopenia manifesting as jaundice in a young male

Idiopathic adulthood ductopenia manifesting as jaundice in a young male Idiopathic adulthood ductopenia manifesting as jaundice in a young male Deepak Jain*,1, H. K. Aggarwal 1, Avinash Rao 1, Shaveta Dahiya 1, Promil Jain 2 1 Department of Medicine, Pt. B.D. Sharma University

More information

P rimary biliary cirrhosis (PBC) is a chronic cholestatic liver

P rimary biliary cirrhosis (PBC) is a chronic cholestatic liver 265 LIVER DISEASE Hyperlipidaemic state and cardiovascular in primary biliary cirrhosis M Longo, A Crosignani, P M Battezzati, C Squarcia Giussani, P Invernizzi, M Zuin, M Podda... See end of article for

More information

Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis

Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis 168 Original Article Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis Ramin Behroozian 1*, Mehrdad Bayazidchi 1, Javad Rasooli 1 1. Department

More information

Evaluation Process for Liver Transplant Candidates

Evaluation Process for Liver Transplant Candidates Evaluation Process for Liver Transplant Candidates 2 Objectives Identify components of the liver transplant referral to evaluation Describe the role of the liver transplant coordinator Describe selection

More information

Is Serum Bilirubin Concentration the Only Valid Prognostic Marker in Primary Biliary Cirrhosis?

Is Serum Bilirubin Concentration the Only Valid Prognostic Marker in Primary Biliary Cirrhosis? Is Serum Bilirubin Concentration the Only Valid Prognostic Marker in Primary Biliary Cirrhosis? PIOTR KRZESKI, 1 WLODZIMIERZ ZYCH, 1 EWA KRASZEWSKA, 2 BOHDAN MILEWSKI, 3 EUGENIUSZ BUTRUK, 1 AND ANDRZEJ

More information

Extrahepatic Biliary Obstruction. Ductal Diseases: Stones Tumors. Acute Injury: Viral Hepatitis Toxin (APAP/Etoh) Reye s Shock.

Extrahepatic Biliary Obstruction. Ductal Diseases: Stones Tumors. Acute Injury: Viral Hepatitis Toxin (APAP/Etoh) Reye s Shock. Extrahepatic Biliary Obstruction Stones Tumors Ductal Diseases: Ductal Diseases: Primary Biliary Primary Biliary Cirrhosis Cirrhosis Sclerosing Cholangitis Sclerosing Cholangitis Acute Injury: Viral Hepatitis

More information

Chronic liver disease in an ageing population

Chronic liver disease in an ageing population Age and Ageing 2009; 38: 11 18 C The Author 2008. Published by Oxford University Press on behalf of the British Geriatrics Society. doi: 10.1093/ageing/afn242 All rights reserved. For Permissions, please

More information

Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment

Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment Edited by Keith D. Lindor Professor of Medicine MayoClinic 200 First

More information

Outcome and Characteristics of Patients on the Liver Transplant Waiting List: Shiraz Experience

Outcome and Characteristics of Patients on the Liver Transplant Waiting List: Shiraz Experience 63 Original Article Outcome and Characteristics of Patients on the Liver Transplant Waiting List: Shiraz Experience F Khademolhosseini 1, SA Malekhosseini 2, H Salahi 2, S Nikeghbalian 2, A Bahador 2,

More information

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

2. Liver blood tests and what they mean p2 Acute and chronic liver screen Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised

More information

Anaesthetic considerations and peri-operative risks in patients with liver disease

Anaesthetic considerations and peri-operative risks in patients with liver disease Anaesthetic considerations and peri-operative risks in patients with liver disease Dr. C. K. Pandey Professor & Head Department of Anaesthesiology & Critical Care Medicine Institute of Liver and Biliary

More information